Cookie Preferences
By clicking “Accept All”, you agree to the storing of cookies on your device to enhance site navigation, analyze site usage and assist in our marketing efforts as outlined in our cookie policy.
Strictly Necessary (Always Active)
Cookies required to enable basic website functionality.
Cookies helping us understand how this website performs, how visitors interact with the site, and whether there may be technical issues.
Cookies used to deliver advertising that is more relevant to you and your interests.
Cookies allowing the website to remember choices you make (such as your user name, language, or the region you are in).

Ventures

Invest in breakthrough healthtech solutions that transform patients' lives.

00:00
/
00:00
00:00
/
00:00
Invest in transformative health innovations
Invest in transformative health innovations

We vet over 1500 innovations yearly and identify, build, and invest in 20 to 25 ventures that address crucial, unmet needs in the healthcare sector. Our ventures lead in areas such as personalized medicine, AI diagnostics, and medical devices, all of which show substantial potential for growth, return, and impact.

00:00
/
00:00
00:00
/
00:00
Invest alongside NLC
Invest alongside NLC

As an investor in an NLC venture, you always invest alongside NLC. Our team of 80+ experts offers comprehensive support to our ventures, including regulatory guidance, product development assistance, and clinical trial setup. This extensive, tailored support system de-risks your investment and enhances the likelihood of venture success. Single-company investments start at €25K.

00:00
/
00:00
00:00
/
00:00
Invest with impact
Invest with impact

By investing in one of our ventures, you help bring transformative health solutions to patients in need, directly impacting their lives. NLC is a certified B Corp and supports UN Sustainable Development Goals 3, 9, and 17, our funds are SDFR-9 compliant, which means we adhere to the strictest impact regulations. Investing in NLC ventures can be your pathway to high-impact capital deployment.

Receive the latest investment opportunities that match your interests, directly in your inbox. Stay informed and never miss out.

a highlight from our portfolio

Angiogenesis Analytics

Angiogenesis Analytics

Angiogenesis Analytics is transforming prostate cancer diagnosis by integrating artificial intelligence with advanced ultrasound technology. Our mission is to make the detection of prostate cancer quicker, more affordable, and significantly less invasive than traditional methods. By pioneering the innovative PCAVision technology, we are setting new standards in healthcare.
Visit website
Download documents
PEP Health

PEP Health

PEP Health is revolutionizing how healthcare providers understand and improve patient experiences by leveraging machine-learning technology to give healthcare organizations, regulators, and insurers the real-time, actionable insights they need to have a direct and dramatic impact on patient experiences.
Visit website
Download documents
Aspect Neuroprofiles
Machine-learning to improve diagnosis and management of autism

Aspect Neuroprofiles is tackling the challenges of diagnosing and treating Autism Spectrum Disorder (ASD) by combining EEG technology with Artificial Intelligence. Their method objectively measures brain activity related to ASD, improving diagnosis accuracy and predicting treatment effectiveness. This approach aims to shift from subjective assessments to objective physiological measurements, offering hope for millions affected by ASD and mental health issues.

Active
🇳🇱 Netherlands
Aspect Neuroprofiles
Startric
Revolutionizing tricuspid valve repair with minimally invasive solutions

StarTric, created by cardiovascular experts, developed a new, less invasive device to fix a serious heart valve problem, Tricuspid Regurgitation (TR). Addressing Tricuspid Regurgitation (TR), a severe condition with high mortality rates, StarTric's device offers a safer alternative to open-heart surgery. The technology can be implanted via a transfemoral catheter, combining the safety of minimally invasive methods with the proven efficacy of the Clover technique, aiming to provide effective treatment to millions of TR patients worldwide who currently lack suitable options.

Active
🇮🇹 Italy
Startric
Pryfiber
Flexible micro-endoscopy for spaces unreachable with current endoscope

The Pryfiber single multimode optical fiber endoscope, with an ultrathin diameter of less than 300 microns, uses an AI algorithm for real-time calibration to create accurate images. This minimally invasive technology allows for precise diagnostics and treatment in areas like joints, cardiac arteries, and neurosurgery, offering a safer and more effective alternative to traditional, more invasive methods.

Active
🇬🇧 United Kingdom
Pryfiber
ProVascTec
Transforming arterial disease treatment with cell therapy

ProVascTec offers a novel solution for chronic arterial disease, focusing on peripheral arterial disease (PAD) and chronic limb ischemia. Unlike traditional treatments like angioplasty or bypass surgery, ProVascTec aims to stimulate vascular tissue growth using mesenchymal stem cells, reducing complications and improving blood flow. This innovative approach has the potential to benefit millions of patients suffering from PAD worldwide.

Active
🇮🇪 Ireland
ProVascTec
Wavefront
Transforming live-cell imaging using AI technology

Wavefront is revolutionizing live-cell imaging with their AI-driven computational microscope, offering a stain-free imaging technique powered by patented quantitative-phase-imaging (QPI) technology. This approach eliminates the need for costly and invasive chemical staining, preserving cell integrity with real-time visualization of cellular structures with precision and detail. Wavefront's innovative solution has transformative potential research across diverse fields, from cancer research to clinical diagnostics.

Active
🇪🇸 Spain
Wavefront
Bilihome
Uncompromised bonding for newborns with wearable therapy

Bilihome aims to revolutionize jaundice treatment for newborns by bringing safe and effective phototherapy from the hospital to the comfort of home. Currently, traditional methods require babies to be isolated in hospitals, disrupting bonding and caregiving between parents and infants. Bilihome's solution integrates blue light therapy into a comfortable garment, allowing newborns to receive treatment while being held, breastfed, and cared for as usual. This patient-centered innovation enables natural care at home, freeing up hospital bed space and promoting family-centric care.

Active
🇳🇱 Netherlands
Bilihome
Capnosway
Direct CO2 measurement at the patient's nose or mouth, simplifying setup and improving accuracy

Capnosway introduces a CO2 monitoring device designed to address the shortcomings of traditional anesthesia. Developed by Philips, this solution directly measures CO2 concentration at the patient's mouth or nose without the need for air sampling. By eliminating procedures, and potential errors associated, Capnosway ensures accurate and efficient monitoring for medical professionals.

Active
🇳🇱 Netherlands
Capnosway
Loresa
Improving access to laparoscopy in low-resource settings

Laparoscopic surgery, while effective, faces limitations in low-resource areas due to cost and sustainability concerns associated with CO2 insufflation. Gasless laparoscopy provides an alternative, that are costly and difficult to use. To address these challenges, LORESA has developed an affordable and user-friendly gasless laparoscopy retractor, designed with input from surgeons worldwide, offering improved usability and cost-effectiveness. This innovation, aims to democratize laparoscopic techniques, benefiting rural hospitals and developing communities.

Active
🇳🇱 Netherlands
Loresa

Our impact

15
Countries active in
2.4M
Patients impacted
20-25
Ventures built annually
70+
Active ventures in our portfolio
80+
Healthcare experts
€160M+
Raised by NLC ventures

Explore our 2024 Impact report

Woman with hands in the air in nature
Maurits Schouten
00:00
/
00:00
I consider the medical sector to be very attractive. However, without the right expertise, network, and diversification, the risks can be significant. NLC removes these barriers and creates an attractive opportunity for me to participate as an investor in this sector.
Maurits Schouten

Maurits Schouten

Impact investor and Board Member of PYM

Peter Veldman
00:00
/
00:00
What I really like about NLC and what triggered my investment in the company is the strong culture and the quality of the team. NLC is able to de-risk the innovation cycle by building ventures at scale, thereby playing a leading role in shaping the future of healthcare.
Peter Veldman

Peter Veldman

Advisor and previous Deputy Head of Fund Operations at EQT Group

Invest in a portfolio of companies

A formal clothed man on a bridge in the city

Create a healthier future with us

Lars Olthof
Head of Venture Finance, Venture Investment Director